en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
1/2024
vol. 99
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Opis przypadku

SETD5 gene mutation as the cause of short stature

Aleksandra Maria Roztoczyńska
1
,
Dorota Roztoczyńska
2
,
Antoni Pyrkosz
3
,
Artur Mazur
4

1.
Department of Medicine, University of Rzeszow, Rzeszów, Poland
2.
Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics, Institute of Pediatrics, Jagiellonian University Medical College, Kraków, Poland
3.
Department of General and Clinical Genetics, College of Medical Sciences, Institute of Medical Sciences, University of Rzeszów, Rzeszów, Poland
4.
Second Department of Pediatrics, Pediatric Endocrinology and Diabetology, Clinical Province Hospital No. 2, Medical College, University of Rzeszów, Poland
Pediatr Pol 2024; 99 (1): 94-98
Data publikacji online: 2024/03/02
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


An 8-year-old boy was referred to the Clinic of Pediatric Endocrinology due to his short stature. The child comes from P II B II, was born naturally, with birth weight 2970 g. He had dysmorphism and a height of 118 cm (3rd centile). Growth hormone (GH) deficiency and other causes of short stature were excluded. A genetic panel was performed using next generation sequencing, which revealed a pathogenic variant in the SETD5 gene, with which growth deficiency is not typically associated. Literature reports suggest that genetically determined conditions with transcriptional effects, GH deficiency, and intellectual disability may overlap phenotypically. The most likely cause of short stature in this case is a genetic mutation in the SETD5 gene. The boy requires multidisciplinary care, including auxological assessment, growth monitoring, puberty assessment, and pediatric and endocrinological care. All children with short stature and dysmorphic features or body proportion abnormalities who receive GH therapy require genetic testing.